Methods for administration and formulations for the treatment of regional adipose tissue
Provided herein are pharmaceutical formulations, methods, and systems for treating regional fat deposits and fat-related conditions and indications. Methods comprise administering a pharmaceutical formulation comprising a long-acting beta-2 adrenergic receptor agonist, for example, salmeterol, suitable for subcutaneous administration. Formulations comprise a pharmaceutical formulation that is suitable for subcutaneous injection comprising: (a) a lipophilic long-acting selective beta-2 adrenergic receptor agonist, or a salt thereof; and (b) at least one subcutaneously acceptable inactive ingredient.
1. An aqueous formulation comprising a non-sustained release formulation suitable for subcutaneous injection that comprises:
(a) an adipose tissue-reducing lipophilic long-acting selective beta-2 adrenergic receptor agonist or a salt thereof, that comprises a dose of up to about 2 micrograms of the agonist and that is suitable for subcutaneous injection; and
(b) at least one subcutaneously acceptable inactive ingredient.
2. The formulation of claim 1 wherein the formulation is formulated as a dose of up to about 1 microgram of the beta-2 adrenergic receptor agonist.
3. The formulation of claim 1 wherein the formulation is formulated as a dose of up to about 500 nanograms of the beta-2 adrenergic receptor agonist.
4. The formulation of claim 1 wherein the formulation is formulated as a dose of up to about 20 nanograms of the beta-2 adrenergic receptor agonist.
5. The formulation of claim 1 wherein the formulation is formulated to be administered using a single needle, multiple needles, or a needleless injection device.
6. The formulation of claim 1 wherein the dose of the beta-2 adrenergic receptor agonist is formulated to be administered through at least 2 sub-doses.
7. The formulation of claim 1 wherein the dose of the beta-2 adrenergic receptor agonist is formulated to be administered through at least 10 sub-doses.
8. The formulation of claim 1 wherein the lipophilic long-acting selective beta-2 adrenergic receptor agonist is salmeterol xinafoate.
9. The formulation of claim 8 wherein the dose of salmeterol xinafoate is formulated to be administered through at least 2 sub-doses.
10. The formulation of claim 9 wherein a single sub-dose comprises about 20 nanograms of salmeterol xinafoate.
11. A method of treating a patient who has excess adipose tissue or reducing adipose tissue in a patient comprising subcutaneously administering to said patient a non-sustained release pharmaceutical formulation that is suitable for subcutaneous injection, the formulation comprising:
(a) an adipose tissue-reducing lipophilic long-acting selective beta-2 adrenergic receptor agonist or a salt thereof, that comprises a dose of up to about 2 micrograms of the agonist; and
(b) at least one subcutaneously acceptable inactive ingredient.
12. The method of claim 11 wherein the formulation is administered as a dose of up to about 1 microgram of the beta-2 adrenergic receptor agonist.
13. The method of claim 11 wherein the formulation is administered as a dose of up to about 500 nanograms of the beta-2 adrenergic receptor agonist.
14. The method of claim 11 wherein the dose of the beta-2 adrenergic receptor agonist is administered through at least 2 sub-doses.
15. The method of claim 11 wherein the lipophilic long-acting selective beta-2 adrenergic receptor agonist is salmeterol xinafoate.
16. The method of claim 15 wherein the dose of salmeterol xinafoate is administered through at least 10 sub-doses.
17. The method of claim 16 wherein a single sub-dose comprises up to about 50 nanograms of salmeterol xinafoate.
18. The method of claim 11 , wherein the method is a method of treating a patient who has excess adipose tissue.
19. The method of claim 11 , wherein the method is a method of reducing adipose tissue in a patient.